Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation , today announced that the European Commission has approved REVLIMID for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The REVLIMID Marketing Authorisation has been updated to include this new indication in multiple myeloma, building upon the already approved indication of REVLIMID in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
http://ift.tt/1DcljRS
http://ift.tt/1DcljRS
No comments:
Post a Comment